ReviewFrontiers in pharmacology2021
Lipid Metabolism Profiles in Rheumatic Diseases.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Effects of two kinds of marine algae polysaccharides and their oligosaccharides on lipid metabolism and gut microbiota in high-fat diet mice.Microbiology spectrum · 2025Article
- Association of the lipidome with type 1 diabetes and the mediated effect of metabolites: A Mendelian randomization study.Medicine · 2025Article
- Erythrocyte Membrane Fingerprints in the Veterinary Field: The Importance of Membrane Profiling and Its Application in Companion Animals.Biomolecules · 2025Review
- Isorhamnetin: what is theFrontiers in pharmacology · 2024Review
- Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment.Nutrients · 2023Review
- Association Between Lipid Profile and Risk of Incident Systemic Sclerosis: A Nationwide Population-Based Study.Clinical epidemiology · 2023Article
- Incident Rheumatoid Arthritis Following Statin Use: From the View of a National Cohort Study in Korea.Journal of personalized medicine · 2022Article
- The foundations and development of lipidomics.Journal of lipid research · 2022Review
- Risk factors for gallstone disease onset in Japan: Findings from the Shizuoka Study, a population-based cohort study.PloS one · 2022Article
- Plasma Metabolome Normalization in Rheumatoid Arthritis Following Initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy.Metabolites · 2021Article
- Targeting immunometabolism by active ingredients derived from traditional Chinese medicines for treatment of rheumatoid arthritis.Chinese herbal medicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases are a group of chronic autoimmune disorders that involve multiple organs or systems and have high mortality. The mechanisms of these diseases are still ill-defined, and targeted therapeutic strategies are still challenging for physicians. Recent research indicates that cell metabolism plays important roles in the pathogenesis of rheumatic diseases. In this review, we mainly focus on lipid metabolism profiles (dyslipidaemia, fatty acid metabolism) and mechanisms in rheumatic diseases and discuss potential clinical applications based on lipid metabolism profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.